G36 (50 μg/kg, s.c., single dose) demonstrates significant GPER antagonistic activity in the ovariectomy-induced estrogen-dependent uterine hyperplasia C57Bl6 mouse model, effectively inhibiting E2-induced uterine epithelial cell proliferation[1].
| Animal Model: | Ovariectomy-induced estrogen-dependent uterine proliferation in C57Bl6 mice model[1] |
| Dosage: | 50 μg/kg |
| Administration: | Subcutaneous injection (s.c.), single dose |
| Result: | Significantly reduced E2-induced uterine epithelial proliferation by inhibiting cell proliferation. |
